ConductScience.org, home

Paper31300331

Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial.

Tinto H and 17 others. Lancet Infect Dis, 2019. Cited by 54 papers, by iCite.

Cite this record

ConductScience Library. Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial. Papers, record 31300331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31300331

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial.
PubMed
Journal
Lancet Infect Dis
PubMed
Year
2019
PubMed
Publication types
Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
54
iCite
Relative citation ratio, by iCite
2.45
iCite
Revised in PubMed
2020-06-10
PubMed

Authors18

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tinto HHalidou
2Otieno WWalter
3Gesase SSamwel
4Sorgho HHermann
5Otieno LLucas
6Liheluka EEdwin
7Valéa IInnocent
8Sing'oei VValentine
9Malabeja AAnangisye
10Valia DDaniel
11Wangwe AAnne
12Gvozdenovic EEmilia
13Guerra Mendoza YYolanda
14Jongert EErik
15Lievens MMarc
16Roman FFrançois
17Schuerman LLode
18Lusingu JJohn

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
MalariaMajor topic
Malaria VaccinesMajor topic
Severity of Illness IndexMajor topic
VaccinationMajor topic
Africa
Child
Child, Preschool
Female
Humans
Incidence
Infant
Male

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT02207816An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in AfricaBackgroundYes

Source ClinicalTrials.gov

Download CSV of trials

Cited by41

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 54 citations.

PMIDTitleJournalYearIn PapersSource
41882671Public health impact of catch-up vaccination or additional booster doses with pre-erythrocytic malaria vaccine R21/Matrix-M: a modelling study.BMC Med2026https://conductscience.org/library/papers/41882671PubMed
41873526Robust Bioconjugated Antigens Induce Immune Responses Preventing Malaria Infection and its Transmission.Small2026https://conductscience.org/library/papers/41873526PubMed
41629565mRNA vaccination overcomes haemozoin-mediated impairment of whole-parasite malaria vaccines in mice.Nat Microbiol2026https://conductscience.org/library/papers/41629565PubMed
41279441mRNA vaccination overcomes hemozoin-mediated impairment of whole parasite vaccine efficacy for malaria.bioRxiv2025https://conductscience.org/library/papers/41279441PubMed
40975080
Sustained efficacy of the RTS,S/AS01E malaria vaccine over 50 months of follow-up when used in full-dose or fractional-dose regimens in young children in Ghana and Kenya: final results from an open-label, phase 2b, randomised controlled trial.
Lancet Glob Health2025https://conductscience.org/library/papers/40975080PubMed
40799456Mapping climate change-driven epidemics.Front Epidemiol2025https://conductscience.org/library/papers/40799456PubMed
39854359A systematic review on malaria and Tuberculosis (TB) vaccine challenges in sub-Saharan African clinical trials.PLoS One2025https://conductscience.org/library/papers/39854359PubMed
38764069IgG and IgM responses to the Plasmodium falciparum asexual stage antigens reflect respectively protection against malaria during pregnancy and infanthood.Malar J2024https://conductscience.org/library/papers/38764069PubMed
38441731Malaria vaccine efficacy, safety, and community perception in Africa: a scoping review of recent empirical studies.Infection2024https://conductscience.org/library/papers/38441731PubMed
38438123Could Less Be More? Accounting for Fractional-Dose Regimens and Different Number of Vaccine Doses When Measuring the Impact of the RTS,S/AS01E Malaria Vaccine.J Infect Dis2024https://conductscience.org/library/papers/38438123PubMed
38430916Integration of the RTS,S/AS01 malaria vaccine into the Essential Programme on Immunisation in western Kenya: a qualitative longitudinal study from the health system perspective.Lancet Glob Health2024https://conductscience.org/library/papers/38430916PubMed
37872492Background malaria incidence and parasitemia during the three-dose RTS,S/AS01 vaccination series do not reduce magnitude of antibody response nor efficacy against the first case of malaria.BMC Infect Dis2023https://conductscience.org/library/papers/37872492PubMed
37793915Malaria vaccine-related adverse events among children under 5 in sub-Saharan Africa: systematic review and meta-analysis protocol.BMJ Open2023https://conductscience.org/library/papers/37793915PubMed
36547910Polypharmacological Cell-Penetrating Peptides from Venomous Marine Animals Based on Immunomodulating, Antimicrobial, and Anticancer Properties.Mar Drugs2022https://conductscience.org/library/papers/36547910PubMed
36504817Vesicular stomatitis virus-based vaccine targeting plasmodium blood-stage antigens elicits immune response and protects against malaria with protein booster strategy.Front Microbiol2022https://conductscience.org/library/papers/36504817PubMed
36146602Mouse Models for Unravelling Immunology of Blood Stage Malaria.Vaccines (Basel)2022https://conductscience.org/library/papers/36146602PubMed
36119062Safety and immunogenicity of BK-SE36 in a blinded, randomized, controlled, age de-escalating phase Ib clinical trial in Burkinabe children.Front Immunol2022https://conductscience.org/library/papers/36119062PubMed
36093265RTS,S/AS01 malaria vaccine (Mosquirix®): a profile of its use.Drugs Ther Perspect2022https://conductscience.org/library/papers/36093265PubMed
35915227Vaccine co-display of CSP and Pfs230 on liposomes targeting two Plasmodium falciparum differentiation stages.Commun Biol2022https://conductscience.org/library/papers/35915227PubMed
35899811Malaria Transmission Intensity Likely Modifies RTS, S/AS01 Efficacy Due to a Rebound Effect in Ghana, Malawi, and Gabon.J Infect Dis2022https://conductscience.org/library/papers/35899811PubMed

See all 41 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/31300331

GET https://conductscience.org/api/papers/v1/31300331/cited_by?page=2